Fetal Cardiac Functions in Fasting Pregnant Women

November 16, 2025 updated by: Sanliurfa Education and Research Hospital

Evaluation of Fetal Cardiac Functions in Fasting Pregnant Women

In this study, we aimed to evaluate fetal cardiac functions after a fasting period of at least 10 days. The purpose of this study was to determine the unexpected effects of fasting on fetal cardiac functions.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Pregnancies at 24-34 weeks of gestation who present to our hospital for routine antenatal follow-up will be evaluated. As the study group, singleton uncomplicated pregnancies with at least 10 days of fasting will be assessed. All ultrasonographic examinations will be conducted within the last 2 hours of the fasting period. The control group will consist of healthy pregnant women who do not fast, with singleton uncomplicated pregnancies between 24-34 weeks, matched for age, parity, and gestational age.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Sanliurfa, Turkey (Türkiye), 63100
        • Sanliurfa Education and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Singleton uncomplicated pregnancies that present for routine antenatal follow-up between 24-34 weeks of gestation.

Description

Inclusion Criteria:

  • Singleton, uncomplicated pregnancies that have been fasting for at least the last 10 days
  • Present for routine antenatal follow-up between 24-34 weeks of gestation

Exclusion Criteria:

  • Multiple pregnancy
  • Premature rupture of membranes
  • Chorioamnionitis
  • Placental abruption
  • Severe fetal growth restriction
  • Congenital fetal anomalies
  • Preeclampsia
  • Oligohydramnios
  • Maternal diabetes -Conditions where fasting is contraindicated for the mother. -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Singleton uncomplicated pregnancies with at least 10 days of fasting.
Procedure: Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.
All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
The control group will consist of healthy pregnant women who do not fast, with singleton uncomplicat
Procedure: Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.
All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Singleton uncomplicated pregnancies with at least 10 days of fasting.
Time Frame: Fetal echocardiographic findings after at least 10 days of fasting.
Fetal echocardiographic findings after at least 10 days of fasting.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sanliurfa Education and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2025

Primary Completion (Actual)

June 30, 2025

Study Completion (Estimated)

November 30, 2025

Study Registration Dates

First Submitted

March 23, 2025

First Submitted That Met QC Criteria

March 23, 2025

First Posted (Actual)

March 28, 2025

Study Record Updates

Last Update Posted (Actual)

November 18, 2025

Last Update Submitted That Met QC Criteria

November 16, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ŞEAH/fasting card

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fasting Pregnant Women

Clinical Trials on Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe